Discover details of the first randomized, multicenter Phase III study to compare the safety and efficacy of mirvetuximab soravtansine vs investigator’s choice of chemotherapy in women with folate receptor-α-positive, platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancer.
This retrospective analysis evaluates chemotherapy-induced nausea and vomiting (CINV)-related hydration needs with palonosetron or granisetron extended-release subcutaneous (GERSC), approved in 2016 for CINV prevention.
This review summarizes the past decade of immunotherapy for non-small-cell lung cancer, gives an updated overview of trials in this field, and the context of future development in this exciting field.
Discover the issues concerning tissue-biomarker development and the hurdles faced in reaching the goal of truly personalized medicine.
Discover the case of a heavily pretreated patient with recurrent advanced squamous cell carcinoma of the cervix who had exhausted all available treatments and demonstrated a striking response to pembrolizumab.
In this article from Future Oncology, the author considers the data supporting the sequential use of available EGFR TKIs and key considerations for selection of first-line treatment.
How do factors such as night work and light-at-night exposure increase a woman’s breast cancer risk? Find out in this editorial from Breast Cancer Management.
Discover whether radiotherapy may have a promising role in synergistically enhancing the systemic response to immune checkpoint inhibition in this editorial from Future Oncology.
In this editorial from Future Oncology, discover how oncolytic viruses may be utilized to target and destroy tumor cells in a currently underexplored immunotheraputic approach.